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ABSTRACT
Introduction: This short case series presents the
results from 5 patients with bilateral chronic
diabetic macular edema (DME), 12 months after
they were initially treated with ILUVIEN
[0.2 lg/day fluocinolone acetonide (FAc)].
Methods: Ten eyes from five patients with
pseudophakic lenses were investigated. Patients
had bilateral, chronic DME and had received
prior laser and anti-VEGF therapy. Visual and
anatomic outcomes were investigated
12 months post-FAc implant in both eyes.
Results: At baseline, central retinal
thickness (CRT) was 645.3 ± 176.1 microns
(mean ± standard deviation), intraocular
pressure (IOP) was 13.7± 3.6 mmHg and visual
acuity (VA) was 44.5 ± 18.6 Early Treatment
Diabetic Retinopathy Study (ETDRS) letters.
Mean CRT improved at 6 months (341.7 ± 169.7
microns) and 12months (287.4± 103.1microns)
and there were concurrent improvements in VA
(ETDRS letters were 56± 16 and 55± 16 at 6 and
12 months, respectively). Mean IOP was
stable throughout and B21mmHg. Left and
right eyes were compared in the 5 patients by
plotting changes in CFT, IOP and VA at
12 months, from baseline levels.
Conclusion: This bilateral case series
demonstrates the effectiveness of a sustained,
controlled low dose of FAc in the management
of bilateral DME over a 12-month period. The
FAc implant has shown to work well in
treatment of bilateral DME, although longer
follow-up of these patients is still needed.
Funding: Publication charges were funded by
Alimera Sciences Ltd.
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CASE SERIES
In everyday clinical practice, patients frequently
present with bilateral diabetic macular edema
(DME), yet there is a paucity of reported data on
the bilateral use of DME therapies [1]. ILUVIEN
[fluocinolone acetonide (FAc) implant] is
indicated for the treatment of vision
impairment associated with chronic DME,
considered insufficiently responsive to
available therapies [2]. A single implant in the
affected eye is recommended, with the fellow
eye being available for therapy but not at the
same time or visit as the first eye [2]. This
inevitably means that treatment of the fellow
eye is delayed; however, early intervention is
important in the management of DME as
prolonged edema can lead to irreversible
damage and permanent vision loss [3].
The structural and functional responses
following bilateral intravitreal injections of
the FAc implant have been reported
previously [4]. The objective of this case series
is to report the structural and functional
responses 12 months after intravitreal
injection of the FAc implant.
Data are presented from 10 eyes. The
demographics for the group and prior
therapies are presented in Table 1. Prior to
intravitreal injection of the FAc implant, all
patients had received at least one macular laser
therapy for DME. Patients had also received an
average of 8.9 (range 3–19) intravitreal
injections of an anti-VEGF and 1.2 (range 0–3)
intravitreal injections of triamcinolone
acetonide. This article does not contain any
new studies with human or animal subjects
performed by any of the authors.
Figure 1 plots central retinal thickness (CRT)
for each patient and Table 2 shows the mean
changes from baseline. There was a decrease in
Fig. 1 Individual patient (eyes 1–10) plots of central
retinal thickness (microns) at baseline (black line) and
6 months (blue line) and 12 months (red line) after
intravitreal injection of the ﬂuocinolone acetonide implant
Table 2 Mean visual acuity, central retinal thickness and intraocular pressure at baseline and 6 and 12 months after
intravitreal injection of the ﬂuocinolone acetonide implant
Measure Baseline 6 months 12 months
Visual acuity, ETDRS letters 44.5 ± 18.6 ?11.0 ± 13.1 ?10.5 ± 13.0
Central retinal thickness, lm 645.3 ± 176.1 -303.6 ± 238.7 -357.9 ± 200.3
Intraocular pressure, mmHg 13.7 ± 3.6 ?1.8 ± 4.5 ?2.3 ± 4.0
Data are presented as mean ± standard deviation
ETDRS Early Treatment Diabetic Retinopathy Study
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CRT for 9 of the 10 patients at month 6 or
month 12. A single patient (patient 9) initially
showed a small (?16 microns) increase in CRT
at 6 months but a much greater reduction
(-182 microns) at 12 months indicating a
delayed response, whereas for patient 10 the
changes at months 6 and 12 were comparatively
smaller (-22 microns at month 6 and ?2
microns at months 12). Overall, mean CRT
decreased by -303.6 ± 238.7 microns
(-42.1 ± 31.5%) and -357.9 ± 200.3 microns
(-50.9 ± 24.2%) at 6 and 12 months,
respectively, from a baseline of 645.3 ± 176.1
microns.
Figure 2 plots visual acuity (VA) in Early
Treatment Diabetic Retinopathy Study (ETDRS)
letters for each patient and Table 2 shows the
mean changes from baseline. At 6 and
12 months, VA was sustained or improved in 9
out of 10 patients with letter gains from
baseline ranging between 0 and 35 ETDRS
letters. Overall, mean VA increased by
11.0 ± 13.1 and 10.5 ± 13.0 ETDRS letters after
6 and 12 months, respectively, from a baseline
of 44.5 ± 18.6 ETDRS letters.
Intraocular pressure (IOP) was also measured
at baseline (mean of 13.7 ± 3.6 mmHg),
6 months (mean 15.5 ± 4.0 mmHg) and
12 months (mean 16.0 ± 3.3 mmHg). Table 2
shows the mean changes from baseline. In all
cases, IOP remained B21 mmHg.
CONCLUSION
The patients followed up in our bilateral case
series show clinical improvement up to
12 months after intravitreal FAc implantation.
Over 12 months, nine out of ten patients had
sustained and improved VA with mean
improvements of 10.5 letters, and a mean
reduction of -357.9 microns in CRT from
baseline with no patients experiencing a rise
of IOP above 21 mmHg.
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